Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Operations (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Cash from Operations data on record, last reported at 6067000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 219.71% year-over-year to 6067000.0; the TTM value through Dec 2025 reached 55827000.0, up 440.7%, while the annual FY2025 figure was 55827000.0, 440.7% up from the prior year.
  • Cash from Operations reached 6067000.0 in Q4 2025 per MIRM's latest filing, down from 39681000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 39681000.0 in Q3 2025 and bottomed at 40199000.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 12884300.0, with a median of 17776000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: crashed 136.55% in 2021, then surged 896.01% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 33147000.0 in 2021, then dropped by 3.39% to 34270000.0 in 2022, then surged by 51.51% to 16618000.0 in 2023, then surged by 69.5% to 5068000.0 in 2024, then surged by 219.71% to 6067000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 6067000.0 in Q4 2025, 39681000.0 in Q3 2025, and 12040000.0 in Q2 2025.